Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 18/20 | 0.56 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.49 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.49 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4818208 | 0.89 | MCHR1 (0.48) | MCHR1ASIC3TLR8TLR7 | |
| SCHEMBL437488 | 0.84 | MCHR1 (0.58) | MCHR1ASIC3 | |
| SCHEMBL437444 | 0.84 | MCHR1 (0.60) | MCHR1ASIC3 | |
| SCHEMBL440305 | 0.84 | MCHR1 (0.58) | MCHR1ASIC3 | |
| SCHEMBL5358262 | 0.83 | ALDH1A1 (0.42) | MCHR1ASIC3TLR8TLR7 | |
| SCHEMBL441586 | 0.81 | KDM4E (0.60) | MCHR1ASIC3TLR8TLR7 | |
| SCHEMBL437720 | 0.80 | MCHR1 (0.69) | MCHR1 | |
| SCHEMBL436437 | 0.77 | MCHR1 (0.51) | MCHR1 | |
| SCHEMBL6204107 | 0.77 | MCHR1 (0.48) | MCHR1TLR8TLR7 | |
| SCHEMBL438576 | 0.77 | MCHR1 (0.49) | MCHR1ASIC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3562513-B1 | NANORESERVOIRS | UNIV LIEGE (BE) | 2023-08-16 | — | — | EP | claimed |
| EP-2135843-B1 | Nanostructured composite material and biosensor comprising it | TSOUKALIS ACHILLEAS (GR) | 2014-08-13 | — | — | EP | claimed |
| EP-1252222-B1 | PROCESS FOR COATING A SURFACE | NOVARTIS AG (CH) | 2005-11-09 | — | — | EP | claimed |
| US-20090012061-A1 | A Method of Treating Cancer | MERCK SHARP & DOHME CORP. | 2009-01-08 | — | — | US | disclosed |
| EP-1791969-A4 | A METHOD OF TREATING CANCER | MERCK & CO INC (US) | 2008-07-02 | — | — | EP | disclosed |
| EP-1791969-A2 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006031607-A2 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 2006-03-23 | — | — | WO | disclosed |
| EP-1451156-A4 | 4-AMINOQUINOLINE COMPOUNDS | MERCK & CO INC (US) | 2005-05-25 | — | — | EP | disclosed |
| US-20050009815-A1 | 4-Aminoquinoline compounds | DEVITA ROBERT J (US) | 2005-01-13 | — | — | US | disclosed |
| EP-1451156-A1 | 4-AMINOQUINOLINE COMPOUNDS | Merck & Co., Inc. (US) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003045920-A1 | 4-AMINOQUINOLINE COMPOUNDS | MERCK & CO., INC. (US) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012061-A1 | A Method of Treating Cancer | KIF5B, MKI67, KIF2C | MCHR1 2332/4885ASIC3 4004/4885TLR8 1486/4885 |
| US-20050009815-A1 | 4-Aminoquinoline compounds | MCHR1, MCHR2, MC5R | MCHR1 1/4885ASIC3 2061/4885TLR8 3491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.